Introduction
The PROGRESS trial had a "flexible" design, which meant that not all patients received the same antihypertensive regimen. Patients who had had a stroke or transient ischaemic attack in the previous five years were eligible. They were also required to have "no definite indication (such as heart failure) for treatment with an ACE inhibitor and no definite contraindication (such as previous intolerance) to such treatment." The entry criteria did not include blood pressure, but treatment with agents other than angiotensin converting enzyme inhibitors was recommended to patients with uncontrolled hypertension before they entered the trial. Patients were then randomised, on a double blind basis, to either active treatment or placebo. All active treatment patients received treatment with perindopril. Indapamide was added "at the discretion of the individual physician" if a patient had "no specific indication for or contraindication to treatment with a diuretic." 1 After a mean follow up of 3.9 years, the active treatment group as a whole had significantly fewer strokes and major vascular events. However, a prespecified subgroup analysis showed that although participants treated with the combination of perindopril plus indapamide had a significantly lower stroke risk than patients who received double placebo (43% risk reduction; 95% confidence interval 30% to 45%), patients treated with perindopril alone had a stroke risk that was not discernibly different from placebo (5% risk reduction, -19% to 23%). Even though there was significant heterogeneity in the sizes of these treatment effects (P < 0.001), the PROGRESS results are repeatedly presented as amalgamated data. For example, "a flexible blood-pressure-lowering regimen, which included perindopril for all patients and indapamide for 58%, reduced blood pressure by an average of 9/4 mm Hg and the risk of stroke by more than a quarter" distinctly deemphasises the fact that the regimen of perindopril alone had no measurable effect on outcome.
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In the PROGRESS trial, the phrases "active treatment" or "perindopril-based blood-pressure-lowering regimen" refer to amalgamated data from the perindopril alone and perindopril plus indapamide treatment arms. Perindopril alone provided no detectable benefits. Reproduced with permission from Elsevier Shortly after the study was published, an editorial (in line with a small number of earlier critical letters and commentaries [2] [3] [4] ) in the American Journal of Hypertension stated explicitly the two major problems with PROGRESS. Firstly, it is illogical and misleading to combine two treatment arms that have significantly heterogeneous results-if the findings from two trial arms differ substantially "then the findings need to be presented separately and interpreted separately"; secondly, "the major limitation of the PROGRESS trial was the failure to include a group randomized to indapamide alone." 5 These editorialists speculated that indapamide alone may have reduced stroke by as much as 38% (43% for the combined therapy minus 5% for perindopril alone), which would be consistent with the 34% risk reduction seen with low dose diuretics in the primary prevention setting 6 and the 29% risk reduction seen with indapamide alone in the post-stroke antihypertensive treatment study (PATS). 7 However, from the design of PROGRESS, one cannot know whether the benefit seen with combination therapy is due to indapamide alone or to an additive or synergistic effect of indapamide with perindopril. What is clear is that the benefit is not attributable to perindopril alone.
The same editorial also argues that the blood pressure differences between the two arms (5/3 mm Hg for perindopril alone v 12/5 mm Hg for the combined therapy) are unlikely to explain the large difference in stroke reduction. 5 For example, the blood pressure reduction with indapamide alone in the PATS trial was only 5/2 mm Hg, less than the reduction seen with perindopril alone in PROGRESS. Yet indapamide alone in PATS was associated with significant stroke reduction, while perindopril alone in PROGRESS was not. Several other large studies, however, have provided evidence that for most cardiovascular outcomes it is the amount of blood pressure reduction, rather than the particular regimen used, that determines the benefits of treatment. [8] [9] [10] Although this is acknowledged in the PROGRESS paper, it is not expressed in the conclusion, which says of perindopril and indapamide that "treatment with these two agents should now be considered routinely for patients with a history of stroke or transient ischemic attack." 1 Results from major drug trials must be clearly presented to avoid misinterpretation by busy clinicians Contributors and sources: The authors are both academic physicians with an interest in language and how it is used in scientific discourse. RW is a neurologist working mainly in the fields of epilepsy and electroencephalography; CZ is an internist working mainly in the fields of palliative care and social science in medicine. This article was written after the PROGRESS trial was brought to the authors' attention by events surrounding the management of a patient in their teaching hospital.
Competing interests: None declared.
